Managed Care Opportunities with Newer Therapies for Type 2 Diabetes Web Activity

• Chapter 1: The Impact of Newer T2DM Therapies and the Risk of Comorbidities
• Chapter 2: Managed Care Decision Making in an Era of New T2DM Therapies
• Release Date: May 8, 2020
• Expiration Date: November 30, 2021
• Estimated Time to Complete Activity:
• Chapter 1: 0.75 hour
• Chapter 2: 0.75 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

John Buse, MD, PhD                                         Professor of Medicine Executive Associate Dean for Clinical Research University of North Carolina School of Medicine Click here for biography Jeffrey Dunn, PharmD, MBA                                                     (Formerly) Vice President, Clinical Strategy and                          Programs and Industry Relations                                   Magellan Rx Management Click here for biography

Target Audience

• Managed medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations
• Pharmacy directors, registered nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
Diabetes affects multiple organs systems and is associated with life-threatening complications such as chronic kidney disease and cardiovascular (CV) disease, including heart failure. Individuals with type 2 diabetes mellitus (T2DM) are 2-to-4 times more likely to develop and die from CV disease than their healthy peers. The financial burden associated with T2DM is significant; more than 20% of health care dollars are spent treating diabetes or its complications. These observations suggest a need to develop treatment strategies to mitigate T2DM disease progression as well as reduce the CV disease burden. This educational activity is designed to improve the knowledge and competence among managed care professionals and HCDMs regarding the potential impact of newer T2DM therapies (e.g., DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors) on CV and renal outcomes.

Educational Objectives 
At the conclusion of this activity, participants should be able to demonstrate improved ability to: 

CHAPTER 1:

• Discuss the relationship between diabetes, cardiovascular (CV) disease, heart failure (HF), and chronic kidney disease (CKD), and how newer therapies may reduce the risk of these outcomes.
• Review the recent and emerging cardiovascular outcome trial (CVOT) data.
• Integrate recent T2DM treatment guideline updates and recommendations with managed care algorithms for the management of comorbidities such as CV disease, HF, and CKD.

CHAPTER 2:

• Discuss the relationship between diabetes, cardiovascular (CV) disease, heart failure (HF), and chronic kidney disease (CKD), and how newer therapies may reduce the risk of these outcomes.
• Employ strategies that feature clinical and real-world evidence of the impact of newer agents on CV and renal outcomes.

ACCREDITATION
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Chapter 1: 0.75 CME credit
Chapter 2: 0.75 CME credit

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEU) of the Accreditation Council for Pharmacy Education.
Chapter 1: UAN: JA4008162-9999-20-2062-H01-P, 0.75 contact hour (Application)
Chapter 2: UAN: JA4008162-9999-20-2063-H01-P, 0.75 contact hour (Application)

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.4 contact hours.
Chapter 1: 0.7 contact hour
Chapter 2: 0.7 contact hour

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change. Chapter 1: 0.75 IPCE credit Chapter 2: 0.75 IPCE credit

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.